Mochida Pharmaceutical Co., Ltd. issued a “Notice Concerning Change of Representative Directors and Directors” as an IR disclosure, dated May 12, 2025.
The changes involve both representative directors and other directors, reflecting a reorganization of the company’s top management structure.
The notice forms part of Mochida’s broader governance and leadership refresh aimed at strengthening management and clarifying executive responsibilities.
The changes are scheduled to take effect following approval at the company’s general meeting of shareholders and subsequent board resolutions (as is standard under Japanese corporate law).
The disclosure is listed among Mochida’s IR News on its official website and is also carried on third‑party news/market data platforms such as Kabutan and FirstWord Pharma under the title “Mochida:
Notice Concerning Changes in Directors.”